Brief: Hepion Pharmaceuticals Announces Early Completion Of Enrollment In Phase 2 ‘Altitude-Nash’ Liver Function Trial
05/12/2022 14:31
Dec 5 (Reuters) - Hepion Pharmaceuticals Inc HEPA.O :
* HEPION PHARMACEUTICALS ANNOUNCES EARLY COMPLETION OF
ENROLLMENT
IN PHASE 2 ‘ALTITUDE-NASH’ LIVER FUNCTION TRIAL
* HEPION PHARMACEUTICALS INC - HEPION ENROLLS 60 F3 NASH
SUBJECTS
IN ONLY 12 WEEKS, FACILITATED BY AGILE 3+ NON-INVASIVE TEST
* HEPION PHARMACEUTICALS - CO, SUMMIT CLINICAL RESEARCH,
HEPQUANT
ALIGN TO DELIVER RENCOFILSTAT'S HEPATIC FUNCTION AND NASH
BIOMARKER RESULTS BY Q2, 2023
Source text for Eikon: ID:nGNX8jYLC2
Further company coverage: HEPA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hepion Pharmaceuticals
See all newsBrief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement